Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cobra Biologics

http://www.cobrabio.com

Latest From Cobra Biologics

Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates

Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.

Deals Business Strategies

Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Oxford’s COVID-19 Vaccine Makers To Parallel Clinical Studies

An industry consortium will drive forward new manufacturing processes in parallel with the Oxford group’s COVID-19 vaccine clinical studies; these studies could produce Phase III efficacy results by this autumn.

Coronavirus COVID-19 Manufacturing
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Other Names / Subsidiaries
    • Cognate BioServices
UsernamePublicRestriction

Register